Cochrane · systematic review · CD003374
Platinum‐containing regimens for metastatic breast cancer
Egger, SJ, Willson, ML, Morgan, J, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Breast CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
10
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 40%Moderate 3 · 30%High 3 · 30%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Platinum‐containing regimens for women with metastatic breast cancer unselected for triple‐negative disease
Population: women with metastatic breast cancer unselected for triple‐negative breast cancer (TNBC)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival ‐ trials of metastatic breast cancer participants unselected for TNBC | HR 1.01 [0.92, 1.12] | 16 studies · 2531 participants | High |
Progression‐free survival/time to progression (randomised participants) ‐ trials of metastatic breast cancer participants unselected for TNBC | HR 0.92 [0.84, 1.01] | 13 studies · 1745 participants | Moderate Downgraded: risk of bias, inconsistency, indirectness |
Objective tumour response rate (assessable participants) ‐ trials of metastatic breast cancer participants unselected for TNBC | RR 1.11 [1.04, 1.19] | 23 studies · 3252 participants | Low Downgraded: risk of bias, inconsistency, indirectness |
Platinum‐containing regimens for women with metastatic triple‐negative breast cancer
Population: women with metastatic triple‐negative breast cancer (mTNBC)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival ‐ trials of mTNBC participants | HR 0.75 [0.57, 1] | 3 studies · 391 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Progression‐free survival/time to progression (randomised participants) ‐ trials of mTNBC participants | HR 0.59 [0.49, 0.72] | 3 studies · 391 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Objective tumour response rate (assessable participants) ‐ trials of mTNBC participants | RR 1.33 [1.13, 1.56] | 5 studies · 878 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Platinum‐containing regimens and toxicity profile
Population: women with metastatic breast cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Nausea/vomiting* grade 3 or 4 (safety population) by type of platinum agent in platinum regimen | RR 0.77 | 7 studies · 1441 participants | Moderate Downgraded: imprecision, inconsistency |
Anaemia grade 3 or 4 (safety population) by type of platinum agent in platinum regimen | RR 1.72 | 7 studies · 1441 participants | High |
Hair loss grade 3 or 4 (safety population) | RR 1.41 | 13 studies · 1452 participants | High |
Leukopenia** grade 3 or 4 (safety population) | RR 1.38 | 22 studies · 3176 participants | Moderate Downgraded: imprecision, inconsistency |